person
as of 2026-07-01Willie Earley
at a glance
Roles: Study Director, Author
KOL signal score 18
7 publications · 5 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Allergan
Roles
Study Director, Author
KOL signal
18
Publications
7 (5 high-value)
Trial investigator
no
Publishes on
1 drugs
Trials led
1
A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia
NCT01412060Phase 3Completed
Publications & congress
7
Long-term adjunctive lumateperone 42 mg treatment in major depressive disorder: Results from a 6-month open-label extension study.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2026 · high-value
The efficacy of lumateperone across symptoms of a major depressive episode with mixed features in patients with major depressive disorder and bipolar disorder: Post hoc analyses.
Journal of affective disorders · 2026 · high-value
Lumateperone for the Treatment of Major Depressive Disorder With Mixed Features or Bipolar Depression With Mixed Features: A Randomized Placebo-Controlled Trial.
Journal of clinical psychopharmacology · 2025 Mar-Apr 01 · high-value
Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.
The American journal of psychiatry · 2025 · high-value
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.
The Journal of clinical psychiatry · 2025 · high-value
Efficacy of Adjunctive Lumateperone 42 mg on Anhedonia and Across a Broad Range of Depressive Symptoms in Major Depressive Disorder: Post Hoc Analysis of a Phase 3, Randomized, Placebo-Controlled Trial.
Neuropsychiatric disease and treatment · 2026
Reply to Letter From Surekha et al: "Lumateperone for Mixed Features in MDD and Bipolar Depression: Advancing Treatment or Raising New Questions".
Journal of clinical psychopharmacology · 2025 Jul-Aug 01
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on